|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Tau truncated by caspase-3 (D421) or tau hyperphosphorylated at Ser396/S404 might play a role in the pathogenesis of AD.
|
28084594 |
2018 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, in vitro and in vivo studies report elevated expression and activation of CASP3 in models of AD.
|
24338704 |
2014 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Extracts were also tested in cell free assays as inhibitors of caspase-1 and matrix metalloproteinase-3 (enzymes associated with inflammation) and caspase-3, which has been shown to cleave protein Tau, an early event in the development of Alzheimer's disease.
|
27473605 |
2017 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The Aβ<sub>1-42</sub> mice that received E2 treatment during the early stage of AD pathology exhibited significant reductions in the production of nitric oxide (NO) and reactive oxygen species (ROS), a marked decrease in the activation of Cytochrome-c/Bax/Bcl-2/caspase-3 pathway, a notable decrease in the level of gliosis a significant increase in the number of synapses (ultrastructural investigation), and a marked upregulation in synaptic function-related proteins compared to mice that received E2 treatment during the late stage of AD pathology.
|
27838872 |
2017 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Oral administration (6 mg/kg per day) for 2 weeks in AD mice leads to improved recognition and spatial memory, reduced caspase-3 cleavage, reversed neuroinflammation, and to accelerated glycogen synthase kinase-3β (pS9GSK-3β) and interleukin (IL-10) levels.
|
31332763 |
2020 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
MiR-155 inhibitor also attenuated upregulation of apoptotic Caspase-3 in the hippocampus of AD rats.
|
31456514 |
2019 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Detection of Active Caspase-3 in Mouse Models of Stroke and Alzheimer's Disease with a Novel Dual Positron Emission Tomography/Fluorescent Tracer [<sup>68</sup>Ga]Ga-TC3-OGDOTA.
|
30755766 |
2019 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
These included targeted delivery of anti-apoptotic protein humanin through the blood-brain barrier (BBB) to neuronal cells, specific inhibition of caspase-3 activation to inhibit the early triggering of AD progression, and delivery of humanin into the cytoplasm of neuronal cells undergoing apoptosis where it exerts its anti-apoptotic functions effectively.
|
23298615 |
2013 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Consistent with the proposal that apoptosis plays a central in role human neurodegenerative disease, caspase-3 activation has recently been observed in stroke, spinal cord trauma, head injury and Alzheimer's disease.
|
10764048 |
2000 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
C/EBP homologous protein (CHOP), caspase-3, caspase-4, and caspase-12, downstream mediators of cell death pathway, were activated in AD.
|
20368688 |
2010 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
To determine a possible role for TDP-43 in Alzheimer's disease (AD), a site-directed caspase-cleavage antibody to TDP-43 based upon a known caspase-3 cleavage consensus site within TDP- 43 at position D219 was designed.
|
18634762 |
2008 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Overall, our study describes a novel mechanism demonstrating that Aβ sequesters caspase-3 activity via direct interaction and facilitates future therapeutic development in AD.
|
27227450 |
2016 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cleavage of tau by caspase-3 was recently confirmed to occur in AD brain as an early event.
|
15750210 |
2005 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In 9 cases of morphologically confirmed AD (CERAD criteria, Braak stages 5 or 6), 5 cases of Parkinson disease (PD) and 3 cases each of Dementia with Lewy bodies (DLB), Progressive Supranuclear Palsy (PSP), and Multiple System Atrophy (MSA), and 7 age-matched controls, the TUNEL method was used to detect DNA fragmentation, and immunohistochemistry for an array of apoptosis-related proteins (ARP), protooncogenes, and activated caspase-3 were performed.
|
10961423 |
2000 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition to their role in amyloid processing, caspase-8 and its downstream effector caspase-3 are involved in synaptic plasticity, learning, memory and control of microglia pro-inflammatory activation and associated neurotoxicity, indicating additional mechanisms that might contribute to AD.
|
28985224 |
2017 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Consistent with a potentially proapoptotic effect of PAR-4 and ceramide, astrocytes surrounding amyloid plaques in brain sections of the 5xFAD mouse (and Alzheimer disease patient brain) showed caspase 3 activation and were apoptotic when co-expressing PAR-4 and ceramide.
|
22532571 |
2012 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, in vitro and in vivo studies reported elevated expression and activation of CASP3 in models of AD.
|
22307387 |
2012 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The removal of AD-treated oocyte spindle before reconstruction (NT(AD+SR)) improved embryo development and reduced caspase-3 activity to levels similar to those in the P(CTL) and NT(CTL) groups.
|
30986366 |
2019 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The optimized TAT-NGF-RA-CURC-QU-CL/PA-lip efficaciously down-regulated the expressions of phosphorylated extracellular signal-regulated protein kinase 1/2 (p-ERK1/2), c-Jun N-terminal protein kinase, p38, tau at serine 202 and caspase-3, and up-regulated the expressions of p-ERK5 and p-cyclic adenosine monophosphate response element-binding protein in Alzheimer's disease Wistar rat model.
|
30716553 |
2019 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this work, the effect of M2000 on the treatment of Alzheimer's disease (AD) was performed by Morris water maze experiment, and the immunological assessments were carried out by Western blot, apoptosis (procaspase-3, Bax/Bcl<sub>2</sub>, P53), enzymatic (superoxide dismutase [SOD]), and nonenzymatic oxidative stress (malondialdehyde [MDA]) tests.
|
28100077 |
2017 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Activated caspase-3 cleaves APP family proteins to release N-terminal fragments (NTFs) and intracellular C-terminal domains (ICDs), which can translocate into the nucleus and induce neurotoxicity in AD.
|
20732423 |
2011 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, a principal caspase pathway from caspase-8 to caspase-3 and/or 7 may contribute to neuron loss in AD brain.
|
16772874 |
2006 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
So we became interested to examine in vitro the effect of phospho-Ser<sup>422</sup> residue on hTau cleavage by caspase-3 which is a crucial upstream event associated with hTau self-assembly leading to AD pathogenesis.
|
27989667 |
2017 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The current investigation focused on detection of PtdSer on the outer leaflet of the bilayer in synaptosomes from brain of subjects with AD and amnestic mild cognitive impairment (MCI), as well as expression levels of apoptosis-related proteins Bcl-2, Bax, and caspase-3.
|
18077176 |
2008 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Hyperphosphorylated truncated protein tau induces caspase-3 independent apoptosis-like pathway in the Alzheimer's disease cellular model.
|
20966551 |
2011 |